Sarepta Therapeutics (NASDAQ:SRPT) Earns "Neutral" Rating from UBS Group

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "neutral" rating reaffirmed by research analysts at UBS Group in a note issued to investors on Monday, MarketBeat Ratings reports.

A number of other research firms have also recently commented on SRPT. Needham & Company LLC cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday. Barclays lifted their price target on Sarepta Therapeutics from $29.00 to $32.00 and gave the company an "overweight" rating in a report on Thursday. Piper Sandler cut their price target on Sarepta Therapeutics from $32.00 to $18.00 and set a "neutral" rating on the stock in a report on Monday. William Blair reissued a "market perform" rating on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Royal Bank Of Canada lowered their price target on Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating, seventeen have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $53.50.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $0.76 during midday trading on Monday, reaching $13.32. 23,680,928 shares of the company traded hands, compared to its average volume of 2,789,064. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -4.95 and a beta of 0.45. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The firm's fifty day moving average price is $28.42 and its two-hundred day moving average price is $67.58. Sarepta Therapeutics has a 12 month low of $11.95 and a 12 month high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same period in the prior year, the company posted $0.73 EPS. The firm's revenue was up 80.2% on a year-over-year basis. On average, equities analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. New York State Teachers Retirement System increased its holdings in shares of Sarepta Therapeutics by 3.3% during the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock valued at $5,065,000 after acquiring an additional 2,512 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $479,000. GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics by 4,682.8% during the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock valued at $2,607,000 after acquiring an additional 39,991 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in Sarepta Therapeutics in the 1st quarter valued at about $821,000. Finally, Cetera Investment Advisers lifted its position in Sarepta Therapeutics by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock valued at $1,359,000 after acquiring an additional 463 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.